Oily SkinNCT06616558
A Study to Assess the Effectiveness of Sunscreen on Oil Control, Moisturization, and Skin Barrier Integrity in Adults With Oily Skin
A study testing Sunscreen SPF 70 in people with Oily Skin, run by JNTL Consumer Health (Brasil) LTDA at 1 site in Brazil.
Trial summary
The purpose of this trial is to evaluate 1) the efficacy of an investigational product (sunscreen) when compared to a control area (without product application) in controlling oiliness, oil shine and the effect on pores appearance in a 12-hour kinetics through a) Instrumental measurements, b) Expert Grader and c)… Read more about this study
- Who is it for?
- Ages 18 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Oily Skin
- What is being tested?
- Sunscreen SPF 70
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 32 participants
- Where
- 1 siteBrazil
- Study dates
- 3 Jun 2024to 30 Jul 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Men and/or Women;
- 18 to 55 years old;
- Phototypes I to VI according to the Fitzpatrick classification;
- Subjects of any ethnicity according to Brazilian Institute of Geography and Statistics (IBGE) criteria
- Integral skin in the test areas;
- Subjects with oily skin, confirmed by instrumental measurements: (sebumetry value of at least 100μg/cm² in the frontal region (average of 3 measurements)).
Show all 18Show fewer
- Subjects with face oil shine - confirmed by Dermatologist;
- Subjects with enlarged pores on the face - confirmed by a Dermatologist;
- Subjects with self-perceived combination/oily or very oily skin on the face;
- Subjects with a self-perceived oil shine on the face;
- Subjects with self-perceived enlarged pores on the face;
- Do not use cosmetic products (including usual soap) the night before the visit and do not wash your face after 10 p.m. the day before the visit;
- For male subjects: who agree to shave 48 hours before the visits;
- Generally, in good health based on medical history reported by the subject;
- Subjects able to read, write, speak, and understand Portuguese;
- Agreeing to adhere to the procedures and requirements of the study and attending the Site on the day(s) and time(s) set for the evaluations;
- Subjects who signed the terms Informed Consent Document (ICD) and Informed Consent Image Disclosure (ICID);
- Intends to complete the study and is willing and able to follow all the study instructions.
Who cannot join
- Has known allergies or adverse reactions to common topical skin care products including sunscreens;
- Presents a skin condition that may confound the study results (specifically psoriasis, eczema, atopic dermatitis, cutaneous xerosis, erythema, or active skin cancer);
- Have primary/secondary lesions (e.g. scars, ulcers, vesicles) or tattoos in the test areas;
- Has self-reported Type 1 or Type 2 diabetes or is taking insulin or another anti-diabetic medication;
- Is taking a medication that would mask an Adverse Event (AE) or confound the study results, including:
- Immunosuppressive or steroidal drugs within 2 months before Visit 1*
Show all 17Show fewer
- Non-steroidal anti-inflammatory drugs within 5 days before Visit 1* (For Oxaprozin and Piroxicam consider 2 weeks before visit 1).
- Antihistamines within 2 weeks before Visit 1* *If an individual is taking one of these medication types, the individual is not considered eligible at screening. However, if a subject begins using one of these medications during the study, the Study Physician should be consulted to consider the impact of the specific medication on subject safety and/or the study results, as described in section "Concurrent/Concomitant Medication".
- Use of any other products capable of interfering with the study evaluations, at the discretion of the dermatologist;
- Subjects who have undergone invasive aesthetic or dermatological treatment in the test area within 2 months prior to the start of the study or during the study;
- Subjects who had used cosmetic products to treat oiliness/shine on the same area (face) within 14 days prior to the start of the study;
- Subjects who are using any medication to treat diseases of the face or eyes;
- Subjects who reported being pregnant, or planning to become pregnant during the study;
- Has a history of or a concurrent health condition/situation which may put the individual at significant risk, confound the study results, or interfere significantly with the individual's participation in the study;
- Simultaneously taking part in another study;
- Being an employee/contractor or close relative of the Principal Investigator, Study Site, or Sponsor;
- Excessive hair in the assessment area that could interfere with instrumental measurements.
Trial locations and contacts
1 site in 1 country.
Brazil1 site
Allergisa Pesquisa Dermato-Cosmética Ltda
Campinas, São Paulo, 13084-791
About this study
Official title: A Single-Center, Open-Label, Randomized Clinical Study to Evaluate the Oil Control Efficacy, Moisture Assessment and Skin Barrier Integrity of an Investigational Product in Adult Participants With Oily Facial Skin
The purpose of this trial is to evaluate 1) the efficacy of an investigational product (sunscreen) when compared to a control area (without product application) in controlling oiliness, oil shine and the effect on pores appearance in a 12-hour kinetics through a) Instrumental measurements, b) Expert Grader and c) Perceived efficacy; 2) the efficacy of an investigational product in reducing oiliness, improving hydration, the pores appearance and the integrity of the skin barrier, after 7 days of use and after 28 ± 2 days of use through instrumental measurements and perceived efficacy questionnaires.
Read the detailed description
The objectives of this study are:
To evaluate the efficacy of an investigational product (sunscreen) when compared to a control area (without product application) in controlling oiliness, oil shine and the effect on pores appearance in a 12-hour kinetics:
- Instrumental measurements with the Sebumeter® SM 815 equipment to assess oiliness control;
- Clinical efficacy evaluation carried out by Expert Grader
- Perceived efficacy through perception questionnaires
To evaluate the efficacy of an investigational product in reducing oiliness, improving hydration, pores appearance and the integrity of the skin barrier, after 7 days of use and after 28 ± 2 days of use, under normal conditions of use in adult participants through the following evaluations:
- Instrumental measurements with the Sebumeter® SM 815 equipment before and after 7 and 28 ± 2 days of use on the face to assess oil reduction;
- Instrumental measurements with the Corneometer® before and after 7 and 28 ± 2 days of use on the face to assess skin hydration;
- Instrumental measurements with the Tewameter® TM 300 before and after 7 and 28 ± 2 days of use on the face to assess the integrity/maintenance of the skin barrier;
- Facial images captured using Visia® CR equipment before and after 7 and 28 ± 2 days of use on the face;
- Perceived efficacy through perception questionnaires answered by research participants after 7 and 28 ± 2 days of use on the face;
- Open-ended emotional statement after 28 ± 2 days.
- Conditions
- Oily Skin
- Being tested
- Sunscreen SPF 70
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Sunscreen SPF 70Other
Participants will topically apply sunscreen SPF 70
Sunscreen SPF 70Other
On the randomized side of the half-face, the product will be applied by a qualified technician
| Study group | Role | What they receive |
|---|---|---|
| Sunscreen Home Usage | Experimental | Participants will use the Sunscreen in normal conditions at home for 28 +/- 2 days, returning to the Site after 7 days of product use, then make the last study visit to complete the final analysis. Receives: Other: Sunscreen SPF 70 |
| Oil Control Assessment Product Application | Experimental | An amount of Investigational Product will be topically applied to malar and forehead areas (after cleansing the face) on one randomized side of the participant's face by a qualified technician to perform the assessment of a 12-hour kinetics. After the evaluations the product will be removed. Receives: Other: Sunscreen SPF 70 |
| Oil control Assessment (Control) | No intervention | On the randomized half-side (malar and forehead areas), no product will be applied and this will be the control for evaluating the product's oil control during the 12-hour kinetics. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants With Adverse Events
Number of participants with adverse events will be reported. An adverse event is any untoward medical occurrence in a clinical study participant temporally associated with the clinical investigation, whether or not the event has a causal relationship to the participants' participation in the trial. It is therefore any unfavorable and unintended sign (including an abnormal finding), symptom, or disease that occurs during the trial. This can include any occurrence that is new in onset, an aggravation of severity/frequency of a baseline condition, or abnormal results of diagnostic procedures, including laboratory test abnormalities.
Measured: Up to 28 days
Change From Baseline in Skin Oil Control Assessment During 12-hour Kinetics
Change from baseline in skin oil control will be reported. The facial oil control will be assessed by a trained technician using instrumental measurements with the Sebumeter SM 815. The Sebumeter measures amount of sebum per area.
Sebumetric measurements will be taken in the forehead region of each half of the face during a 12-hour kinetics. One half of the forehead region will contain the Investigational Product and the other half will be the control, with no product applied.
Measured: Day 1: Baseline, 30 minutes, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours and 12 hours
Participant's Self-perceived Questionnaire to Assess the Clinical Effectiveness of the Sunscreen During 12-hour Kinetics
Participant's self-perceived questionnaire to assess the clinical effectiveness of the sunscreen on oil and shine control. Participants will answer 6 questions and rate as: totally disagree, disagree, neither agree nor disagree, agree and totally agree. The area to be evaluated is half face with and without product applied.
Measured: Day 1: Baseline, 30 minutes, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours and 12 hours
Change From Baseline in Clinical Effectiveness on Oil Shine
Change from Baseline in Clinical Effectiveness Assessment on Oil Shine will be reported. A 10-point ordinal scale (0 to 9) will be used. Therefore, as it is an ordinal scale, the intermediate points do not have an established definition. The evaluated area will be each half face and the scale to be used is defined from 0 = Dull, matte skin to 9 = Very intense oil shine, very oily skin. The time-points will me compared in terms of statistical improvement (improvement of oiliness shine (regulation)) versus the baseline.
Measured: Day 1: Baseline, 30 minutes, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours and 12 hours
Change From Baseline in Clinical Effectiveness on Pores Appearance
Change from Baseline in Clinical Effectiveness Assessment on Pores Appearance will be reported. A 10-point ordinal scale (0 to 9) will be used. Therefore, as it is an ordinal scale, the intermediate points do not have an established definition. The evaluated area will be each half face and the scale to be used is defined from 0 =small, hardly visible to 9 = large, easily visible. The time-points will me compared in terms of statistical improvement (improvement in the appearance (number and/or size) of pores) versus the baseline.
Measured: Day 1: Baseline, 30 minutes, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours and 12 hours
Change From Baseline in Skin Oil Control Assessment
Change from baseline in skin oil control will be reported. The facial oil control will be assessed by a trained technician using instrumental measurements with the Sebumeter SM 815. The Sebumeter measures amount of sebum per area. Sebumetric measurements will be taken in the forehead region.
Measured: Baseline (Day 1), Day 7 and Day 28 +/- 2 days
Change From Baseline in Skin Barrier Integrity
Change from baseline in skin barrier integrity will be reported. The facial skin barrier will be assessed by a trained technician using instrumental measurements with the Tewameter TM 300. The Tewameter measures transepidermal water loss (TEWL) that is the flow of water out of the skin. TEWL measurement will be taken in the nasolabial region of one randomized half of the face.
Measured: Baseline (Day 1), Day 7 and Day 28 +/- 2 days
Change From Baseline in Skin Hydration
Change from baseline in skin hydration will be reported. The facial skin hydration will be assessed by a trained technician using instrumental measurements with the Corneometer® CM825. The Corneometer measures the dielectric constant of the skin. The dielectric constant of skin will change with water content of the stratum Corneum, that can be converted into arbitrary units of hydration. Corneometer measurement will be taken in the malar region of one randomized half of the face.
Measured: Baseline (Day 1), Day 7 and Day 28 +/- 2 days
Number of Participants with Improvement From Baseline in Skin Appearance Assessed Using the Visia-CR Facial Imaging Booth
Facial images will be captured using the Visia CR Facial Imaging Booth. Three Three images per participant will be captured: right lateral, left lateral and frontal. The captured images will be further analyzed using specific image analysis software to evaluate improvement in the attributes of oiliness reduction, shine reduction, pore size reduction, and pore clearance, versus baseline and also between time-points.
Measured: Baseline (Day 1), Day 7 and Day 28 +/- 2 days
Participant's Self-perceived Questionnaire to Assess the Clinical Effectiveness of the Sunscreen on Day 7
Participant's self-perceived questionnaire to assess the clinical effectiveness of the sunscreen on Day 7 will be reported. Participants will answer 1 question on overall satisfaction with sunscreen by scoring as: disliked a lot, disliked, neither liked nor disliked, liked and liked a lot. Additionally, 15 attributes will be presented to be rated as: totally disagree, disagree, neither agree nor disagree, agree and totally agree.
Measured: Day 7
Participant's Self-perceived Questionnaire to Assess the Clinical Effectiveness of the Sunscreen on Day 28
Participant's self-perceived questionnaire to assess the clinical effectiveness of the sunscreen on Day 28 will be reported. Participants will answer 1 question on overall satisfaction with sunscreen by scoring as: disliked a lot, disliked, neither liked nor disliked, liked and liked a lot. Additionally, 15 attributes will be presented to be rated as: totally disagree, disagree, neither agree nor disagree, agree and totally agree.
Measured: Day 28
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Sep 2024
- Study start3 Jun 2024
- Primary completion30 Jul 2024
- Study completion30 Jul 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Oily SkinStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 32 participants (actual)
Sponsor and investigators
- Lead sponsor
- JNTL Consumer Health (Brasil) LTDA
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Gabrielli Brianezi, PhD, Principal investigator, Johnson & Johnson Consumer Inc. (J&JCI)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06616558
- Sponsor's protocol ID
- CS2024SK100142
- Status last verified
- Jun 2024
- First submitted
- 13 Aug 2024
- Last updated
- 27 Sep 2024
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Sep 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Single-Center, Open-Label, Randomized Clinical Study to Evaluate the Oil Control Efficacy, Moisture Assessment and Skin Barrier Integrity of an Investigational Product in Adult Participants With Oily Facial Skin
- ClinicalTrials.gov ID
- NCT06616558
- Acronym / sponsor ID
- CS2024SK100142
- Conditions
- Oily Skin
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 32 participants (actual)
- Lead sponsor
- JNTL Consumer Health (Brasil) LTDAIndustry (pharma, biotech, devices)
- Study start
- 3 Jun 2024 (actual)
- Primary completion
- 30 Jul 2024 (actual)
- Study completion
- 30 Jul 2024 (actual)
- First posted
- 27 Sep 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this trial is to evaluate 1) the efficacy of an investigational product (sunscreen) when compared to a control area (without product application) in controlling oiliness, oil shine and the effect on pores appearance in a 12-hour kinetics through a) Instrumental measurements, b) Expert Grader and c) Perceived efficacy; 2) the efficacy of an investigational product in reducing oiliness, improving hydration, the pores appearance and the integrity of the skin barrier, after 7 days of use and after 28 ± 2 days of use through instrumental measurements and perceived efficacy questionnaires.
Detailed description
The objectives of this study are:
To evaluate the efficacy of an investigational product (sunscreen) when compared to a control area (without product application) in controlling oiliness, oil shine and the effect on pores appearance in a 12-hour kinetics:
- Instrumental measurements with the Sebumeter® SM 815 equipment to assess oiliness control;
- Clinical efficacy evaluation carried out by Expert Grader
- Perceived efficacy through perception questionnaires
To evaluate the efficacy of an investigational product in reducing oiliness, improving hydration, pores appearance and the integrity of the skin barrier, after 7 days of use and after 28 ± 2 days of use, under normal conditions of use in adult participants through the following evaluations:
- Instrumental measurements with the Sebumeter® SM 815 equipment before and after 7 and 28 ± 2 days of use on the face to assess oil reduction;
- Instrumental measurements with the Corneometer® before and after 7 and 28 ± 2 days of use on the face to assess skin hydration;
- Instrumental measurements with the Tewameter® TM 300 before and after 7 and 28 ± 2 days of use on the face to assess the integrity/maintenance of the skin barrier;
- Facial images captured using Visia® CR equipment before and after 7 and 28 ± 2 days of use on the face;
- Perceived efficacy through perception questionnaires answered by research participants after 7 and 28 ± 2 days of use on the face;
- Open-ended emotional statement after 28 ± 2 days.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Sunscreen Home Usage | Experimental | Other: Sunscreen SPF 70Participants will use the Sunscreen in normal conditions at home for 28 +/- 2 days, returning to the Site after 7 days of product use, then make the last study visit to complete the final analysis. |
| Oil Control Assessment Product Application | Experimental | Other: Sunscreen SPF 70An amount of Investigational Product will be topically applied to malar and forehead areas (after cleansing the face) on one randomized side of the participant's face by a qualified technician to perform the assessment of a 12-hour kinetics. After the evaluations the product will be removed. |
| Oil control Assessment (Control) | No intervention | –On the randomized half-side (malar and forehead areas), no product will be applied and this will be the control for evaluating the product's oil control during the 12-hour kinetics. |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (18 listed)
- Men and/or Women;
- 18 to 55 years old;
- Phototypes I to VI according to the Fitzpatrick classification;
- Subjects of any ethnicity according to Brazilian Institute of Geography and Statistics (IBGE) criteria
- Integral skin in the test areas;
Key exclusion criteria (17 listed)
- Has known allergies or adverse reactions to common topical skin care products including sunscreens;
- Presents a skin condition that may confound the study results (specifically psoriasis, eczema, atopic dermatitis, cutaneous xerosis, erythema, or active skin cancer);
- Have primary/secondary lesions (e.g. scars, ulcers, vesicles) or tattoos in the test areas;
- Has self-reported Type 1 or Type 2 diabetes or is taking insulin or another anti-diabetic medication;
- Is taking a medication that would mask an Adverse Event (AE) or confound the study results, including:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Sunscreen SPF 70Participants will topically apply sunscreen SPF 70 | Other | Sunscreen Home Usage |
| Sunscreen SPF 70On the randomized side of the half-face, the product will be applied by a qualified technician | Other | Oil Control Assessment Product Application |
Primary outcome
Number of Participants With Adverse Events
Time frame: Up to 28 days
Number of participants with adverse events will be reported. An adverse event is any untoward medical occurrence in a clinical study participant temporally associated with the clinical investigation, whether or not the event has a causal relationship to the participants' participation in the trial. It is therefore any unfavorable and unintended sign (including an abnormal finding), symptom, or disease that occurs during the trial. This can include any occurrence that is new in onset, an aggravation of severity/frequency of a baseline condition, or abnormal results of diagnostic procedures, including laboratory test abnormalities.
Change From Baseline in Skin Oil Control Assessment During 12-hour Kinetics
Time frame: Day 1: Baseline, 30 minutes, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours and 12 hours
Change from baseline in skin oil control will be reported. The facial oil control will be assessed by a trained technician using instrumental measurements with the Sebumeter SM 815. The Sebumeter measures amount of sebum per area. Sebumetric measurements will be taken in the forehead region of each half of the face during a 12-hour kinetics. One half of the forehead region will contain the Investigational Product and the other half will be the control, with no product applied.
Participant's Self-perceived Questionnaire to Assess the Clinical Effectiveness of the Sunscreen During 12-hour Kinetics
Time frame: Day 1: Baseline, 30 minutes, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours and 12 hours
Participant's self-perceived questionnaire to assess the clinical effectiveness of the sunscreen on oil and shine control. Participants will answer 6 questions and rate as: totally disagree, disagree, neither agree nor disagree, agree and totally agree. The area to be evaluated is half face with and without product applied.
Change From Baseline in Clinical Effectiveness on Oil Shine
Time frame: Day 1: Baseline, 30 minutes, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours and 12 hours
Change from Baseline in Clinical Effectiveness Assessment on Oil Shine will be reported. A 10-point ordinal scale (0 to 9) will be used. Therefore, as it is an ordinal scale, the intermediate points do not have an established definition. The evaluated area will be each half face and the scale to be used is defined from 0 = Dull, matte skin to 9 = Very intense oil shine, very oily skin. The time-points will me compared in terms of statistical improvement (improvement of oiliness shine (regulation)) versus the baseline.
Change From Baseline in Clinical Effectiveness on Pores Appearance
Time frame: Day 1: Baseline, 30 minutes, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours and 12 hours
Change from Baseline in Clinical Effectiveness Assessment on Pores Appearance will be reported. A 10-point ordinal scale (0 to 9) will be used. Therefore, as it is an ordinal scale, the intermediate points do not have an established definition. The evaluated area will be each half face and the scale to be used is defined from 0 =small, hardly visible to 9 = large, easily visible. The time-points will me compared in terms of statistical improvement (improvement in the appearance (number and/or size) of pores) versus the baseline.
Change From Baseline in Skin Oil Control Assessment
Time frame: Baseline (Day 1), Day 7 and Day 28 +/- 2 days
Change from baseline in skin oil control will be reported. The facial oil control will be assessed by a trained technician using instrumental measurements with the Sebumeter SM 815. The Sebumeter measures amount of sebum per area. Sebumetric measurements will be taken in the forehead region.
Change From Baseline in Skin Barrier Integrity
Time frame: Baseline (Day 1), Day 7 and Day 28 +/- 2 days
Change from baseline in skin barrier integrity will be reported. The facial skin barrier will be assessed by a trained technician using instrumental measurements with the Tewameter TM 300. The Tewameter measures transepidermal water loss (TEWL) that is the flow of water out of the skin. TEWL measurement will be taken in the nasolabial region of one randomized half of the face.
Change From Baseline in Skin Hydration
Time frame: Baseline (Day 1), Day 7 and Day 28 +/- 2 days
Change from baseline in skin hydration will be reported. The facial skin hydration will be assessed by a trained technician using instrumental measurements with the Corneometer® CM825. The Corneometer measures the dielectric constant of the skin. The dielectric constant of skin will change with water content of the stratum Corneum, that can be converted into arbitrary units of hydration. Corneometer measurement will be taken in the malar region of one randomized half of the face.
Number of Participants with Improvement From Baseline in Skin Appearance Assessed Using the Visia-CR Facial Imaging Booth
Time frame: Baseline (Day 1), Day 7 and Day 28 +/- 2 days
Facial images will be captured using the Visia CR Facial Imaging Booth. Three Three images per participant will be captured: right lateral, left lateral and frontal. The captured images will be further analyzed using specific image analysis software to evaluate improvement in the attributes of oiliness reduction, shine reduction, pore size reduction, and pore clearance, versus baseline and also between time-points.
Participant's Self-perceived Questionnaire to Assess the Clinical Effectiveness of the Sunscreen on Day 7
Time frame: Day 7
Participant's self-perceived questionnaire to assess the clinical effectiveness of the sunscreen on Day 7 will be reported. Participants will answer 1 question on overall satisfaction with sunscreen by scoring as: disliked a lot, disliked, neither liked nor disliked, liked and liked a lot. Additionally, 15 attributes will be presented to be rated as: totally disagree, disagree, neither agree nor disagree, agree and totally agree.
Participant's Self-perceived Questionnaire to Assess the Clinical Effectiveness of the Sunscreen on Day 28
Time frame: Day 28
Participant's self-perceived questionnaire to assess the clinical effectiveness of the sunscreen on Day 28 will be reported. Participants will answer 1 question on overall satisfaction with sunscreen by scoring as: disliked a lot, disliked, neither liked nor disliked, liked and liked a lot. Additionally, 15 attributes will be presented to be rated as: totally disagree, disagree, neither agree nor disagree, agree and totally agree.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Sep 2024.
- Individual participant dataSharing planned: No
Related trials for Oily Skin
RecruitingPhase 2
FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)
Dermatomyositis (DM), Juvenile Dermatomyositis (JDM)
Recruiting
Dermal and Ophthalmological Acceptability and Comedogenicity Assessment of a Cosmetic Product
Oily Skin, Acne Prone Skin
RecruitingPhase 4
Prospective Evaluation of Topical Almond Oil vs Hydroquinone
Skin Pigmentation
RecruitingEarly Phase 1
Tart Cherry and Omega-3's for Aromatase Inhibitor Musculoskeletal Symptoms
Breast Cancer, Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS)
Active, not recruitingPhase 1
Fish Oil Supplementation During Pregnancy for Prevention of Asthma, Eczema and Allergies in Childhood
Asthma, Eczema
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Gabrielli Brianezi, PhD principal investigator
Johnson & Johnson Consumer Inc. (J&JCI)
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Sunscreen SPF 70 in people with Oily Skin, run by JNTL Consumer Health (Brasil) LTDA at 1 site in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 18 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Sep 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants With Adverse Events (time frame: Up to 28 days). The study lists 11 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Sep 2024.